Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 32INDUSTRY 5OTHER_GOV 1NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Lymphoma 1Glioma 1Central Nervous System Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Cisplatin 24Radiotherapy 18Carboplatin 18Paclitaxel 17Vincristine 15Cyclophosphamide 14Etoposide 13Filgrastim 12Doxorubicin 12Gemcitabine 11Temozolomide 10Cytarabine 9Topotecan 8Docetaxel 8Methotrexate 7Irinotecan 7Granulocyte Colony-Stimulating Factor 7Dexamethasone 7Taxes 6Radiation 6Peripheral Blood Stem Cell Transplantation 6Radiotherapy, Conformal 5Oxaliplatin 5Melphalan 5Fenretinide 5Chemotherapy, Adjuvant 5Capecitabine 5etoposide phosphate 4Trastuzumab 4Platinum 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × NETWORK × selinexor × Clear all
NCT02323880 2025-01-14

Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas

Children's Oncology Group

Phase 1 Completed
59 enrolled 20 charts
CNSLymphoid

Astrocytoma, Brain Neoplasms, Glioma, Lymphoma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡